Today, a Director at Sientra (NASDAQ: SIEN), Kevin Oboyle, bought shares of SIEN for $99.99K.
This recent transaction increases Kevin Oboyle’s holding in the company by 23.48% to a total of $640.8K. In addition to Kevin Oboyle, 6 other SIEN executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Sientra’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $11.07 million and GAAP net loss of $17.83 million. In comparison, last year the company earned revenue of $7.49 million and had a GAAP net loss of $11.42 million. Currently, Sientra has an average volume of 1.01M. The Company has a Price to Book ratio of 11.5542.
Starting in September 2017, SIEN received 14 Buy ratings in a row. Seven different firms, including Canaccord Genuity and Leerink Partners, currently also have a Buy rating on the stock. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $17.00, reflecting a -1.7% downside.
Kevin Oboyle’s trades have generated a 56.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. is a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. Its products include breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders. The company was founded in 2006 by Hani M. Zeini and is headquartered in Santa Barbara, CA.
